4th Patient Centricity and Collaboration World Congress 2023 Europe.

4th PATIENT CENTRICITY & COLLABORATION WORLD CONGRESS 2023 EUROPE

Patient-centric initiatives across the end-to-end value chain

Copthorne Tara Hotel London Kensington, London, UK

Thursday 1st - Friday 2nd June 2023

OPEN Health brings together deep scientific knowledge, global understanding, and broad specialist expertise to support our clients in improving health outcomes and patient wellbeing.

Gold sponsor

The Method: A Life in a Day

A Life in a Day was created in 2015 by The Method, a British company specialising in immersive and interactive learning and development experiences to effect behaviour change. Led by Mark Doyle, co-founder of The Method and an entrepreneur and actor with more than 15 years’ experience in the creative arts, A Life in a Day aims to support patient-centric care by helping the pharmaceutical and healthcare industries understand and relate to the daily challenges and choices patients face. It is an award-winning, innovative training simulation that uses Doyle’s acting experience as a foundation on which to elicit an emotional response and inspire change, It is rooted in patient insight and designed to be completed during a typical working day to reflect the reality of living with a chronic health condition. For more information, visit https://alifeinaday.co.uk

Silver sponsor

Blueprint Medicines is a global precision therapy company that invents life-changing therapies for people with cancer and blood disorders. Applying an approach that is both precise and agile, we create medicines that selectively target genetic drivers, with the goal of staying one step ahead across stages of disease. Since 2011, we have leveraged our research platform, including expertise in molecular targeting and world-class drug design capabilities, to rapidly and reproducibly translate science into a broad pipeline of precision therapies. Today, we are delivering our approved medicines to patients in the United States and Europe, and we are globally advancing multiple programs for systemic mastocytosis, lung cancer, breast cancer and other genomically defined cancers, and cancer immunotherapy. For more information, visit www.BlueprintMedicines.com and follow us on Twitter (@BlueprintMeds) and LinkedIn.

Associate Sponsor

Evidera is a business within Pharmaceutical Product Development, LLC, (PPD) a leading global contract research organization (CRO), and is a preeminent provider of evidence-based solutions to demonstrate the real-world effectiveness, safety, and value of biopharmaceutical and biotechnology products from early development through loss of exclusivity. We provide integrated scientific expertise and global operational capabilities to help you generate the evidence needed to optimize the market access and commercial potential of your products. Evidera was acquired by PPD in 2016 and originally created in 2013 as an independent company under the ownership of Symphony Technology Group following the acquisition of long-standing health economics, outcomes research, market access, epidemiology, and data analytics practices from United BioSource Corporation (UBC). Evidera has over 35 years of leadership and experience and its legacy brands include MEDTAP, Caro Research, Abt Bio-Pharmaceutical Solutions, MetaWorks, Total Healthcare Group, and Archimedes. Optimizing access with evidence of value, effectiveness, and safety (evidera.com)

Associate sponsor